Alzheimer Society International Congress 2019

ASIC 2019

February 18 - 21, 2019
San Francisco Airport Crowne Plaza

Tel. 1-650-826-2337                     www.alzint.com
Dear colleagues:

We are pleased to welcome you to the 1st Alzheimer Society International Congress (ASIC 2019), San Francisco, February 18-21, 2019.

Alzheimer’s Disease is a progressive and irreversible neurodegenerative disorder that affects millions of people worldwide. Today, more than 5.8 million people in the United States and 45 million people worldwide live with Alzheimer’s. There is currently no cure, no prevention and no treatment of Alzheimer’s disease.

If Dr. Alois Alzheimer were alive today, he would not be able to offer any other treatment to his senile patients than what he provided in the beginning of 1900. Why, after 115 years, FDA (Food and Drug Administration), EMA (European Medicines Agency) and other regulatory agencies in the world are not approving any Alzheimer’s disease modifying drugs and other treatment options?

ASIC 2019 is an open forum to foster interaction, share knowledge and make a difference in our understanding and treatment of Alzheimer’s disease and dementia care. Over the past 40 years since the NIH began funding in research on Alzheimer in 1978, there have been over 150 drug compounds tested as potential therapies were identified that were either abandoned or failed in more than 400 clinical trials.

The Alzheimer International Society and our partners have declared war on Alzheimer’s disease. At the ASIC 2019 we have launched the United Front Against Alzheimer’s, which calls for global research collaboration to accelerate the discovery and development of preventive methods and treatment therapies of Alzheimer’s disease.

We thank our program committee members and volunteers, who have done so much in organizing ASIC 2019. We appreciate our speakers, presenters and groups of sponsors and exhibitors in making the ASIC 2019 program possible. Thank you all for attending and making ASIC 2019 an unforgettable event. Together we can draw the roadmap of Alzheimer research and dementia care, so that others coming after us will be able to carry on to fight the fight.

With warmest regards,

Markku Kurkinen and Lloyd L. Tran
Program Co-Chairs
Alzheimer Society International Congress 2019
**PROGRAM SCHEDULE**

**MONDAY, FEBRUARY 18, 2019**

<table>
<thead>
<tr>
<th>Time</th>
<th>Activity</th>
<th>Time</th>
<th>Activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:00 PM- 05:00 PM</td>
<td>Registration</td>
<td>07:00 AM- 08:00 AM</td>
<td>Registration</td>
</tr>
<tr>
<td>01:00 PM- 05:00 PM</td>
<td>Exhibitor Set-up</td>
<td>08:00 AM- 08:30 AM</td>
<td>Breakfast</td>
</tr>
<tr>
<td>01:00 PM- 04:00 PM</td>
<td>Workgroup: “The Neuroimmune Nexus of Depression and Dementia: Shared Mechanisms and Therapeutic Targets”</td>
<td>08:30 AM- 08:35 AM</td>
<td>Welcome Remark from Program Co-chairs</td>
</tr>
<tr>
<td>01:00 PM- 01:05 PM</td>
<td>Introduction and Welcome Remarks from Co-Chairs</td>
<td>08:40 AM - 10:00 AM</td>
<td>Keynote Session and Panel Discussion on “After 40 years of research failure in Alzheimer’s: Where are we headed?”</td>
</tr>
<tr>
<td>01:05 PM– 01:30 PM</td>
<td>Prof. Giulio M. Pasinetti Icahn School of Medicine at Mount Sinai New York, NY</td>
<td>01:00 PM- 01:05 PM</td>
<td>Lloyd L. Tran, Program Co-Chair</td>
</tr>
<tr>
<td>01:30 PM- 02:00 PM</td>
<td>Dr. Sunnie Kenowsky New York University School of Medicine New York, NY</td>
<td>01:05 PM- 04:00 PM</td>
<td>Les Hamasaki, Director, Alzheimer International Society California, USA</td>
</tr>
<tr>
<td>02:00 PM- 02:30 PM</td>
<td>Dr. Sudeshna Das Massachusetts General Hospital Boston, Massachusetts</td>
<td>01:00 PM– 01:05 PM</td>
<td>Bryce Vissel, Director, Centre for Neuroscience and Regenerative Medicine, University of Technology Sydney, NSW, AUSTRALIA</td>
</tr>
<tr>
<td>02:30 PM- 02:45 PM</td>
<td>Coffee Break</td>
<td>02:45 PM- 03:15 PM</td>
<td>Giulio M Pasinetti The Saunders Family Chair and Professor of Neurology, Icahn School of Medicine at Mount Sinai, New York, USA</td>
</tr>
<tr>
<td>02:45 PM- 03:15 PM</td>
<td>Dr. Chad Smith Icahn School of Medicine at Mount Sinai New York, NY</td>
<td>03:15 PM– 03:45 PM</td>
<td>Leen Kawas, CEO, M3 Biotechnology Seattle, Washington, USA</td>
</tr>
<tr>
<td>03:15 PM– 03:45 PM</td>
<td>Ms. Alice La University of California San Francisco San Francisco, California</td>
<td>02:30 PM- 02:45 PM</td>
<td>Coffee Break- Exhibit and Poster Presentation</td>
</tr>
<tr>
<td>03:45 PM– 4:00 PM</td>
<td>Roundtable Panel Discussion</td>
<td>10:00 AM- 10:30 AM</td>
<td>Session Chair: Rui-Ming Liu</td>
</tr>
<tr>
<td>04:30 PM- 05:15 PM</td>
<td>Depart the SFO Crowne Plaza for Fisherman’s Wharf in San Francisco</td>
<td>10:30 AM- 10:50 AM</td>
<td>Kai C. Sonntag, Woo-In RYU, Wang, LIAO, Ryan A HEALY, Minqi SHEN, Mariana K BORMANN, Hyemyung SEO, Bruce M COHEN</td>
</tr>
<tr>
<td>05:30 PM- 07:30 PM</td>
<td>Sunset Bay Cruise San Francisco</td>
<td>10:55 AM- 11:15 AM</td>
<td>Department of Psychiatry, McLean Hospital, Harvard Medical School- Boston, Massachusetts, USA</td>
</tr>
<tr>
<td>08:30 PM- 09:00 PM</td>
<td>Return to Crowne Plaza Hotel</td>
<td>10:00 AM- 10:30 AM</td>
<td>“Aberrant Cellular Bioenergetics is an Inherent Key Feature in Alzheimer’s Disease”</td>
</tr>
</tbody>
</table>

---

**TUESDAY, FEBRUARY 19, 2019**

<table>
<thead>
<tr>
<th>Time</th>
<th>Activity</th>
<th>Time</th>
<th>Activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:00 PM- 05:00 PM</td>
<td>Registration</td>
<td>07:00 AM- 08:00 AM</td>
<td>Registration</td>
</tr>
<tr>
<td>01:00 PM- 05:00 PM</td>
<td>Exhibitor Set-up</td>
<td>08:00 AM- 08:30 AM</td>
<td>Breakfast</td>
</tr>
<tr>
<td>01:00 PM- 04:00 PM</td>
<td>Workgroup: “The Neuroimmune Nexus of Depression and Dementia: Shared Mechanisms and Therapeutic Targets”</td>
<td>08:30 AM- 08:35 AM</td>
<td>Welcome Remark from Program Co-chairs</td>
</tr>
<tr>
<td>01:00 PM- 01:05 PM</td>
<td>Introduction and Welcome Remarks from Co-Chairs</td>
<td>08:40 AM - 10:00 AM</td>
<td>Keynote Session and Panel Discussion on “After 40 years of research failure in Alzheimer’s: Where are we headed?”</td>
</tr>
<tr>
<td>01:05 PM– 01:30 PM</td>
<td>Prof. Giulio M. Pasinetti Icahn School of Medicine at Mount Sinai New York, NY</td>
<td>01:00 PM- 01:05 PM</td>
<td>Lloyd L. Tran, Program Co-Chair</td>
</tr>
<tr>
<td>01:30 PM- 02:00 PM</td>
<td>Dr. Sunnie Kenowsky New York University School of Medicine New York, NY</td>
<td>01:05 PM- 04:00 PM</td>
<td>Les Hamasaki, Director, Alzheimer International Society California, USA</td>
</tr>
<tr>
<td>02:00 PM- 02:30 PM</td>
<td>Dr. Sudeshna Das Massachusetts General Hospital Boston, Massachusetts</td>
<td>01:00 PM– 01:05 PM</td>
<td>Bryce Vissel, Director, Centre for Neuroscience and Regenerative Medicine, University of Technology Sydney, NSW, AUSTRALIA</td>
</tr>
<tr>
<td>02:30 PM- 02:45 PM</td>
<td>Coffee Break</td>
<td>02:45 PM- 03:15 PM</td>
<td>Giulio M Pasinetti The Saunders Family Chair and Professor of Neurology, Icahn School of Medicine at Mount Sinai, New York, USA</td>
</tr>
<tr>
<td>02:45 PM- 03:15 PM</td>
<td>Dr. Chad Smith Icahn School of Medicine at Mount Sinai New York, NY</td>
<td>03:15 PM– 03:45 PM</td>
<td>Leen Kawas, CEO, M3 Biotechnology Seattle, Washington, USA</td>
</tr>
<tr>
<td>03:15 PM– 03:45 PM</td>
<td>Ms. Alice La University of California San Francisco San Francisco, California</td>
<td>02:30 PM- 02:45 PM</td>
<td>Coffee Break- Exhibit and Poster Presentation</td>
</tr>
<tr>
<td>03:45 PM– 4:00 PM</td>
<td>Roundtable Panel Discussion</td>
<td>10:00 AM- 10:30 AM</td>
<td>Session Chair: Rui-Ming Liu</td>
</tr>
<tr>
<td>04:30 PM- 05:15 PM</td>
<td>Depart the SFO Crowne Plaza for Fisherman’s Wharf in San Francisco</td>
<td>10:30 AM- 10:50 AM</td>
<td>Kai C. Sonntag, Woo-In RYU, Wang, LIAO, Ryan A HEALY, Minqi SHEN, Mariana K BORMANN, Hyemyung SEO, Bruce M COHEN</td>
</tr>
<tr>
<td>05:30 PM- 07:30 PM</td>
<td>Sunset Bay Cruise San Francisco</td>
<td>10:55 AM- 11:15 AM</td>
<td>Department of Psychiatry, McLean Hospital, Harvard Medical School- Boston, Massachusetts, USA</td>
</tr>
<tr>
<td>08:30 PM- 09:00 PM</td>
<td>Return to Crowne Plaza Hotel</td>
<td>10:00 AM- 10:30 AM</td>
<td>“Aberrant Cellular Bioenergetics is an Inherent Key Feature in Alzheimer’s Disease”</td>
</tr>
</tbody>
</table>

---

**Keynote Session and Panel Discussion on “After 40 years of research failure in Alzheimer’s: Where are we headed?”**

- **Markku Kurkinen**, Program Co-Chair, Professor, Wayne State University School of Medicine, Michigan, USA
- **Lloyd L. Tran**, Program Co-Chair, Chairman, NeuroActiva Inc. California, USA
- **Les Hamasaki**, Director, Alzheimer International Society California, USA
- **Bryce Vissel**, Director, Centre for Neuroscience and Regenerative Medicine, University of Technology Sydney, NSW, AUSTRALIA
- **Giulio M Pasinetti** The Saunders Family Chair and Professor of Neurology, Icahn School of Medicine at Mount Sinai, New York, USA
- **Leen Kawas**, CEO, M3 Biotechnology Seattle, Washington, USA
Department of Neurology, Zhongshan Hospital, State Key Laboratory of Medical Neurobiology and Institutes for Brain Science, Fudan University, Shanghai, China.
"Decoding Alzheimer’s disease based on brain glucose hypometabolism: From bench to bedside."

Lew Lim
Vielight Inc.,
Reza Zomorrodi, Temerty Centre for Therapeutic Brain Intervention, Centre for Addiction and Mental Health;
Toronto Ontario, Canada, Genane Loheswaran, Vielight Inc, Canada, Abhiram Pushparaj, Ironstone Product Development Inc., Toronto, Ontario, CANADA.
"Gamma-pulsed Transcranial Photobiomodulation Produces Desired EEG Measures applicable for Alzheimer’s Disease treatment."

Elizabeth Milward, Ritambhara Aryal1, Jason J. Woods1, Elvis Freeman-Acquah1, Kristy L. Martin1, Seak-Lin Ly1, Samuel Kelsey1, and Daniel M Johnstone2.
1 School of Biomedical Sciences and Pharmacy, University of Newcastle, NSW, AUSTRALIA
2 Bosch Institute and Discipline of Physiology, University of Sydney, NSW, AUSTRALIA.
"The Relationship of Iron and Amyloid: Insights from A New Mouse Model of Iron-Loading and Amyloidosis."

Linda L. Chao
University of California, San Francisco & San Francisco VA Medical Center San Francisco, CA, USA
"Effects of Photobiomodulation on Cognitive Function, Cerebral Perfusion and Functional Connectivity in Patients with Dementia."

Sudeshna Das, Emily M. Merrill, Nathan A. Bihlmeyer, Yann Lambert, Gyan P. Srivastava, Timothy W. Clark and Bradley T. Hyman
Department of Neurology, Massachusetts General Hospital and Harvard Medical School Cambridge, MA, USA
"Integrative Omics Analysis to Investigate the Ca2+ Signaling Pathway in Alzheimer’s Disease."

Coffee Break – EXHIBIT and POSTER PRESENTATION

Session Chair: Jerzy Leszek
Wroclaw Medical University Dept. of Psychiatry, Wroclaw, POLAND
"Valentin Bragin
Stress Relief and Memory Training Center- Brooklyn, NY, USA
"A multi-faceted rehabilitation model in Alzheimer’s disease in the context of adjustable and modifiable factors"

Medha Kothari, Prasanta Dey and Ian Maidment
Aston University, Birmingham, UK
"Using Six Sigma Strategy, DMAIC to Improve the Dementia Medicines Management Process within UK Care HomesUsing Six Sigma Strategy, DMAIC to Improve the Dementia Medicines Management Process within UK Care Homes"

Elizabeth Barber
Barber Innovations LLC
Winfield, IL USA
"Therapeutic Benefits of Art, Structure and Nutrition for the Parkinson’s Patient with Alzheimer’s Changes."

Discussion- Conclusion of Day 1

- Deep domain expertise in biopharmaceutical industry.
- Great experience and insight in building great companies
- Breakthrough therapies for un-met needs
- Lead investor in the United Front Against Alzheimer’s

www.TranspacificVC.com
<table>
<thead>
<tr>
<th>Time</th>
<th>Session/Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:00 AM- 04:00 AM</td>
<td>Registration</td>
</tr>
<tr>
<td>07:00 AM- 08:00 AM</td>
<td>Breakfast</td>
</tr>
<tr>
<td>08:00 AM- 08:10 AM</td>
<td>Welcome remarks from the Program Co-Chairs</td>
</tr>
<tr>
<td>08:15 AM- 08:35 AM</td>
<td>Session Chair: Bryce Vissel</td>
</tr>
<tr>
<td>08:40 AM- 09:00 AM</td>
<td>Markku Kurkinen</td>
</tr>
<tr>
<td>09:30 AM- 09:50 AM</td>
<td>Yu-Wen Alvin Huang, Bo Zhou, Marius Wernig, and Thomas Sudhof</td>
</tr>
<tr>
<td>09:50 AM- 10:15 AM</td>
<td>Rammohan Rao</td>
</tr>
<tr>
<td>10:20 AM- 10:40 AM</td>
<td>Lloyd Tran et al. NeuroActiva, Inc.</td>
</tr>
<tr>
<td>10:45 AM- 11:05 AM</td>
<td>Jerzy Leszek</td>
</tr>
<tr>
<td>11:10 AM- 11:30 AM</td>
<td>Man Shing Wong, Yinhui Li, Di Xu, Hei-Nga Chan, See-Lok Ho, and Hung-Wing Li</td>
</tr>
<tr>
<td>11:35 AM- 11:55 AM</td>
<td>Xinhua Zhan, Boryana Stamova and Frank R. Sharp.</td>
</tr>
<tr>
<td>12:15 PM- 01:30 PM</td>
<td>Shauna Yuan, Charisse N. Winston¹, Brent Aulston¹, Edward M. Rockenstein¹, Anthony Adame¹, Olga Prikhodko¹, Kishan N. Dave¹, Priyanka Mishra¹, Robert A. Rissman¹²</td>
</tr>
<tr>
<td>01:30 PM- 02:15 PM</td>
<td>Christopher Heye, Anthony Weiner¹, Janet Sherman¹, Lee Baer¹, Maurizio Fava¹, Cogniscient, Inc</td>
</tr>
<tr>
<td>02:20 PM- 02:40 PM</td>
<td>Claudia Jacova, Samantha Smith and Sara Wong School of Graduate Psychology, Pacific University Hillsboro, OR, USA</td>
</tr>
<tr>
<td>02:45 PM- 03:05 PM</td>
<td>Lloyd Tran et al. NeuroActiva, Inc.</td>
</tr>
<tr>
<td>03:05 PM- 03:30 PM</td>
<td>Jo Ann Pelaez-Fisher</td>
</tr>
<tr>
<td>03:30 PM- 03:50 PM</td>
<td>Jason Woods¹, Hunter Medical Research</td>
</tr>
</tbody>
</table>
Institute, NSW, AUSTRALIA
3 Bosch Institute and Discipline of Physiology, University of Sydney, NSW, AUSTRALIA

"Studies In Improved Models Of Neonatal and Adult Experimental Respiratory Chlamydia Infection Do Not Support Causative Roles For Chlamydia In Alzheimer’s Disease"

Nathan Duval, Alex Sandberg, Srivalli Puttagunta and Daniel Linseman, Knoebel Institute for Healthy Aging University of Denver, Denver, CO, USA
"Treatment with Immunocal, a cysteine-rich whey protein supplement, elevates reelin expression and signaling and ameliorates Alzheimer’s disease-like pathology in a mouse model of Alzheimer’s disease"

04:20 PM- 04:40 PM

04:45 PM- 05:15 PM Discussion- Conclusion of day 2

09:05 AM - 09:25 AM

Elena Paley
Expert Biomed, Inc. & Stop Alzheimer Corp. Homestead, FL USA
"Link of human gut bacterial sequence (ADAS) with Alzheimer’s and associated diseases: ADAS-associated prevalence of fecal metabolites in health and disease"

09:30 AM - 09:50 AM

Zung Tran, Anna Ivashchenko, William KENT and Kate Yzquierdo Medaware Systems, Inc. Broomfield, CO, USA
"Effects of donezezil (Aricept) on cognitive impairment in Alzheimer’s disease and dementia: Multiple instrumentations hinder outcomes assessment”

09:55 AM - 10:15 AM

Harry Goldsmith
University of California, Davis—Retired Glenbrook, NV, USA
"Omental Transposition to the Brain of Alzheimer Patients”

10:15 AM - 10:30 AM Coffee Break

10:30 AM - 10:50 AM Session Chair: Lloyd L. Tran
Program Chair

Federico Goodsaid,1 Harald Hampel,1 Mohammad Afshar, Frédéric Parmentier,1 Coralie Williams1, Adrien Etcheto1, Christopher U Missling1
1Department of Neurology, Sorbonne University, Paris, France, 2Ariana Pharma, Paris, France, 3Regulatory Pathfinders LLC, San Francisco, CA, “Anavex Life Sciences Corp., New York, NY “Longitudinal 148-Week Extension Study for ANAVEX®2-73 Phase 2a Alzheimer’s Disease Demonstrates Maintained Activities of Daily Living Score (ADCS-ADL) and Reduced Cognitive Decline (MMSE) for Patient Cohort on Higher Drug Concentration and Confirms Role of Patient Selection Biomarkers”

www.neuroactiva.com
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 10:55 AM-11:15 AM | **Sunnie Kenowsky**¹, Yongzhao Shao², Carol Torossian³, Muhammad Saad³, Gianna Daffisio³, Alok Vedvyas³, and Barry Reisberg³  
1. Department of Psychiatry, New York University School of Medicine, New York University Langone Health  
2. Departments of Population Health and Environmental Medicine, New York University Langone Health  
3. Department of Psychiatry, New York University School of Medicine, New York University Langone Health  
4. Department of Neurology, New York University Langone Health  
“Effect of Comprehensive, Individualized, Person-Centered Management on Antidepressant’s Usage in Advanced Alzheimer’s Persons in a 28-Week, Randomized, Controlled Trial” |
| 11:20 AM-11:40 AM | **Bruno Bonnechère**  
Laboratory of Anatomy, Biomechanics and Organogenesis, Université Libre de Bruxelles, Brussels, BELGIUM  
“Can we learn by playing? An ecological study using mobile games” |
| 11:45 AM-12:05 PM | **Lon White**¹, Steven Edland¹, Julia Chosy¹, Margaret Flanagan¹, Brenna Cholerton¹, Laura Hemmy¹, and Tom Montine¹  
¹Pacific Health Research and Education Institute, Honolulu, HI, USA  
²University of California at San Diego  
³University of Minnesota School of Medicine  
⁴Stanford University School of Medicine  
“Development and use of a resilience index to identify protective factors” |
| 12:10 PM-1:15 PM | **Lunch** |
| 1:15 PM-1:35 PM | **Katrin Schenk**¹, Eleonore Bayen², Natalie Manley³, Tamary Braley³, Jennifer Merrilees³, Amy Clark⁴, Brad Zylstra¹  
¹Department of Physics, Randolph College, Lynchburg, VA, USA  
²Memory and Aging Center, Department of Neurology, University of California San Francisco, San Francisco, CA, USA  
³Division of Geriatrics, Department of Internal Medicine, University of Nebraska Medical Center, Omaha NE, USA  
⁴Department of Civil and Environmental Engineering, University of California, Berkeley, Berkeley, CA, USA  
“Patterns of lifespace and physical activity from persons with Alzheimer’s disease and dementia provide insight into caregiver challenges and successes” |
| 1:40 PM-2:00 PM | Van Park  
University of California at San Francisco (UCSF), School of Nursing, Department of Community Health Systems, San Francisco, CA USA  
Vy Ton, San Jose State University, Department of Health Science and Recreation; Gwen Yeo, Stanford University, School of Medicine; Quyen Vuong, International Children Assistance Network, and Dolores Gallagher-Thompson, Stanford University, School of Medicine San Francisco, CA, USA  
“Culturally Tailored, Evidence-based Program for Vietnamese American Dementia Caregivers to Reduce Stress and Depression: A Randomized Control Trial” |
| 2:00 PM-4:00 PM | **WORKSHOP:** “Effective Interventions for Depression in Dementia Family Caregivers: Review and Recommendations” |
| 2:00 PM-2:30 PM | Barbara Sommer MD- Associate Professor in Psychiatry, Emerita Dept. of Psychiatry & Behavioral Sciences Stanford Univ. School of Medicine  
“Psychiatric Treatment of the Patient with Dementia: Concerns in Treating the Caregiver” |
| 2:30 PM-3:00 PM | Rita Ghatak, Ph.D- Former Director, Stanford Aging Adult Services, Associate Director, Optimal Aging Center  
“Continuum of Care for Families Facing Dementia” |
| 3:00 PM-3:15 PM | Coffee Break |
| 3:15 PM-3:45 PM | **Dolores Gallagher-Thompson, PhD, ABPP**  
Board Certified in Clinical Psychology and Geropsychology Professor Emerita, Dept. of Psychiatry & Behavioral Sciences Stanford Univ. School of Medicine  
“Using CBT and Other Forms of Psychotherapy to Reduce Depression in Family Caregivers.” |
| 3:45 PM-4:00 PM | Q&A Discussion |
| 4:00 PM-4:30 PM | Discussion- Conference Conclusion Meeting Adjourned |
**Ram Bhatt**, M. Sinkovich, O. Ramos, Herbert Chow  
ICB International, Inc.  
La Jolla, CA, USA  
"Meeting the Unmet Medical Need for Neurodegenerative Diseases"

**Phillip DiGiacomo**, Samuel Webb, Ed Plowey, Maged Goubran, Sherveen Parivash, Brian Rutt, Don Born, Michael Zeineh  
Stanford University  
Stanford, CA, USA  
"Altered oxidation state supports neuroinflammatory role of iron in Alzheimer's disease"

**Ivan Fedoriv**, Anna Fedoriv, Inna Fedoriv, Tkachuk Nazar, Anton Fedoriv, Olesya Fedoriv  
Applied Nanobiotech Research Lab  
Chernivtsi, Ukraine.  
"Stabilization of Protein Prenylation is an Emerging Approach for Correcting Alzheimer’s Diseases"  
"New Metabolic Strategies for Bioethereal substance, functional genomics, isopentenyl tRNAs and resistance to Alzheimer’s disease."

**Nicole M. Gatto**, Jennifer Garcia-Cano, Crissy Irani, Grace J. Lee  
1 Claremont Graduate University  
2 Loma Linda University  
Claremont, CA USA  
"Observed physical function is associated with better cognition among elderly adults: the Adventist Health Study"

**Jordan M. Glenn**, Nicholas T. Bott, Erica N. Madero, Alex Lange, John Anderson, Doug Newton, Adam Brennan, Elizabeth A. Buffalo, Dorene M. Rentz, Stuart M. Zola, NeuroTrack Technologies  
Redwood City, CA, USA  
"Remote Evaluation of Cognitive Function Using Eye Tracking Metrics from Device-Embedded Webcams"

**Maribella González-Viruet**, Elixmahir Dávila-Marrero, Deborah Pérez-Mojica  
1 Carlos Albizu University  
2 Private Practice  
San Juan, Puerto Rico, USA  
"Trail Making Test, the Case of the Island of Puerto Rico"

**William Grant** and Conor P. Kerley  
1 Sunlight, Nutrition and Health Research Center  
San Francisco, CA USA  
2 Dept. of Paediatric Medicine, National Children’s Hospital, Dublin, IRELAND  
"Dietary risk-modifying factors for cognitive dysfunction, dementia, and Alzheimer’s disease"

**Qing Guo**, Jun Xie, and Sima Asfa,  
Department of Physiology, The University of Oklahoma Health Sciences Center  
Oklahoma City, OK, USA  
"Regulation of Neuronal Necroptosis By Sap-12 In Alzheimer’s Disease"

**Anne Koplin**  
SSM Health/Dean Medical Group  
Milwaukee, WI, USA  
"Behavioral Correlates of Cognitively Healthy Adults"

**Goo Rak Kwon**, Bijen Khagi, Moon-So Kang  
Chosun University, Dong-Gu Gwangju, Republic of Korea  
"Alzheimer’s diseases detection form Brain MRI using VBM and AAL extracted features"

**Fidias E Leon-Sarmiento**, Juan S. Leon-Ariza and Daniel S. Leon-Ariza  
1 University of Pennsylvania, Philadelphia, PA, USA  
2 Mediciencias Research Group, Louisville, KY, USA  
3 UDES, Bucaramanga, Colombia  
"The orbicularis oculi reflexes in Alzheimer’s disease: State of the evidence and meta-analysis"

**Hung Wing Li**, Hei-Nga Chan, Di Xu, See-Lok Ho, Dinggeng HE, Man Shing Wong  
Department of Chemistry, Hong Kong Baptist University  
Hong Kong, China  
"Highly sensitive quantification of Alzheimer’s disease biomarkers by aptamer-assisted amplification"

**Ileana Lorenzini**, Jennifer Levy, Camelia Burciu, Divya Bhatia, Benjamin Rabichow, Doug Clough, and Rita Sattler  
Barrow Neurological Institute  
Phoenix, Arizona, USA  
Human in vitro co-culture system of C9orf72-FTD/ALS patient-derived iPSC neurons and microglial cells to study mechanisms of synaptopathy

**Atul Sunny Luthra**  
McMaster University. Homewood Health Center  
Hamilton, ON, CANADA  
"A New Behavioural Assessment and Intervention Response Inventory: LuBAIR (in persons with dementia)"

**Patricia Martin-Maestro**, Andrew Sproul, Hector Martinez  
1 Feil Family Brain & Mind Research Institute. Weill Cornell Medicine. NY, USA.  
2 The New York Stem Cell Foundation. NY, USA.  
3 The New York Stem Cell Foundation. NY, USA.  
4 Institute for Stroke and Dementia Research. University Hospital. Munich, Germany.  
5 Laboratory of Brain Development and Repair, The Rockefeller University, New York. Stanford University, Stanford, CA, USA.  
"Autophagy induction by Bexarotene promotes mitophagy in Presenilin 1 familial Alzheimer’s disease iPSC-derived neural stem cells"
POSTER PRESENTERS

Elias Michaelis, R. Pal, H. Allen, B. S. J. Blagg, O. Moziconacci, and C. Schöneich, Higuchi Biosciences Center, University of Kansas Kansas, USA
“Protection Against A β-Induced Neuronal Damage by an HSP90 C-terminal Modulator and the Importance of Pyruvate Dehydrogenase Kinase”

Sarah Nasrouel, Julina A. Rattel, Michael Liedlgruber, Josef Marksteiner, Frank H. Wilhelm
1 Division of Clinical Psychology, Psychiatry, and Health Psychology, Department of Psychology, University of Salzburg, Salzburg, AUSTRIA
2 Department of Psychiatry and Psychotherapy A, State Hospital Hall, Hall, AUSTRIA
“Fear Acquisition and Extinction Deficits: Prognostic Markers for Alzheimer’s Disease?”

John Hall Olichney, Charlie DeCarli, Joshua Miller, David Johnson, Sarah Farias PhD, Bruce Hammock, Brittany Dugger, Lee-Way Jin, PhD, Mary McPhail-Cuifo, Kelsey Levinson, Robert Soohoo, Dan Mungas, Danielle Harvey
University of California, Davis
Sacramento, CA, USA
“Can vitamin D supplementation slow cognitive decline in Alzheimer’s disease?”

Jose Rodriguez, Gomez Maribella, Gonzalez Viruet, Lizzette Roman Rosa, and J. Rodriguez Benitez
University of Puerto Rico
San Juan, PR, USA
“Vieques, Puerto Rico, an Island within an Island: A descriptive study of Cognitive Performance in a sample of people 60 years and older”

Ricardo Salazar, Indika V Mallawaarachchi, and Alok K. Dwivedi
Paul L Foster School of Medicine, Department of Psychiatry, Division of Geriatric Psychiatry and Behavioral Neurosciences El Paso, TX, USA
“Cross-ethnic Differences in Peripheral Biomarkers Levels of Inflammatory Cytokines in Patients with Simultaneous Diagnosis of Alzheimer’s disease Dementia and Type II Diabetes Mellitus”

Madhuvanthi Suresh
Abigail Kramer, & Sherry A. Beaudreau
Palo Alto Veterans Affairs Health Care System/Palo Alto University
Palo Alto, CA, USA
“Hearing Impairment and the Occurrence and Severity of Anxiety and Depressive Symptoms in Older Adults with Cognitive Impairment”

Tonita Wroolie, Valentina Ghisays; Katie Watson; Kewei Chen; Erick Riemann, Natalie L. Rasgon
1 Stanford University, School of Medicine
2 Banner Institute
“Pro-inflammatory lipids differentially affect cognitive function and regional cerebral metabolism in APOE4 carriers versus non-carriers”
We are pleased to announce the formation of Journal of the Alzheimer International Society (JAIS). This will be a fully open access journal, Internet-only journal, accessible to all involved or interested in the prevention and treatment of Alzheimer’s disease and dementia care.

JAIS will be a general medical journal featuring scientific, medical, and health content in a wide range of subject areas including: Behavior Science, Epidemiology, Ethics, Genetics and Genomics, Geriatrics, Health Informatics, Health Policy, Imaging, Immunology, Neurology and Neuroscience, Neuroimaging, Neuropathology, Pharmacy and Pharmacology, Physiology, Psychiatry, Public Health, Public Policy, Patient Care and Practice, Sociology, Statistics and Research Methods, Preclinical and Clinical Trials and related subjects.

JAIS will focus on interdisciplinary and translational studies related to: etiology, early detection, disease modifying interventions, and clinical trials of new drugs and neurotech products that can potentially provide preventive and treatment benefits for Alzheimer’s patients.

JAIS will have editorial comments about controversies, the principles of neuroscience practice, dementia care, socio-economics, ethics, and topics of interest to our audience.

In addition to accepting research papers from all over the world, JAIS will have contents provided through the meetings of the Alzheimer Society International Congress (ASIC) to be held normally in February/March and September each year. This content, as well as downloads of papers, will be available at no charge. For those stakeholders around the world who cannot afford a journal, or cannot go to ASIC meetings, JAIS will be their source of information.

When papers are accepted, they will be published within days rather than weeks or months. All papers will be searchable through PubMed Central, a division of PubMed, and will be searchable on PubMed and other commonly-used databases.

If you are interested in becoming involved with JAIS in any of its aspects, please contact us at JAIS@alzint.com

Markku Kurkinen and Lloyd L. Tran
Co-Editors-in-Chief
Journal of the Alzheimer International Society
International United Front Against Alzheimer’s

STRATEGIC PLAN:


2. Accelerate on the development of biomarkers and diagnostics.

3. Harmonize and speed up the AD drug approval processes between regional and international clinical trial systems.

4. Partner with the International Funds Against Alzheimer to raise $1 Billion to fund new concepts and clinical trials of new Alzheimer drugs with proof of safety and efficacy.

5. Focus resources to bring newly approved drugs to the market by the year 2025.

6. Support the evidenced-based Dementia care practices.

IUFAA is funded by a globally diverse group of private and institutional investors, including foundations, endowments, family offices, financial institutions and pension funds.

Alzheimer International Society serves the coordinating body for the United Front Against Alzheimer’s.

For more information, please contact:
Alzheimer International Society
Tel. 1-650-826-2337
www.alzint.com/united.html
NeuroActiva, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of new drugs to treat Alzheimer’s disease. The clinical trial Phase 2A of NA-831 (Traneurocin) in Alzheimer’s patients has shown excellent safety profile with no adverse effects observed. The drug is administered orally in a dosage form for the treatment of Alzheimer’s disease. (www.neuroactiva.com)

Vielight Inc.: Invented in 1995 in Silicon Valley the intranasal photobiomodulation is a non-invasive method of introducing therapeutic photonic energy into the human body. Vielight is poised at the forefront of brain photobiomodulation technology. Vielight combines science with engineering ingenuity to develop devices that incorporate novel methods of delivering photons to the brain and inner systems. (https://vielight.com)

Whealthcare Planning is a mission-driven company dedicated to helping individuals and families more successfully plan for the financial and emotional challenges associated with aging. We provide a unique cloud-based platform offering a suite of innovative tools and educational materials developed in cooperation with thought leaders in geriatrics, psychiatry, and financial planning. Our platform focuses on preparing individuals and families for major life transitions that virtually all older adults confront. (http://www.whealthcareplan.com)

MagQu Co., Ltd. is an innovative diagnostic company that develops highly sensitive, blood-based assays to detect biomarkers of neurodegenerative diseases including those associated with Alzheimer’s Disease (AD) and Parkinson’s disease (PD). The company is a pioneer in the application of ImmunoMagnetic Reduction (IMR)-SQUID-based technology to further inform both the biomarker field and clinical care. We are now providing testing services for 7 plasma biomarkers to research laboratory right directly at our testing service company, MagQu LLC, in Phoenix, USA. (http://www.magqu.com)

TransPacific Venture Capital Partners, Inc.: TransPacific has developed deep domain expertise and insight into the biopharmaceutical and biomedical industry. We apply our experience in building great companies to meet the growing need for improved healthcare products and services, resulting in breakthrough therapies and technologies that have transformed the healthcare industry. We focus on novel therapeutics in major disease areas with unmet needs, such as immunotherapy oncology, neurosciences. TransPacific VC Partners, Inc. is the lead investor of United Front Against Alzheimer’s. (http://www.transpacificvc.com)

eZ-Xpo is a global leader in Virtual Collaborative Network solutions empowering businesses to connect, collaborate, and promote through networks of virtual event marketplaces for lead generation. eZ-Xpo reinvents the trade show and lead generation industry with a revolutionary new approach to virtual events, virtual trade shows, private business networking marketplace, automation to follow up with every prospective customer during and after the event. (http://www.eZ-Xpo.com)